封面
市場調查報告書
商品編碼
2024899

移植診斷市場報告:按組件、技術、器官類型、應用、最終用戶和地區分類的市場規模、佔有率、趨勢和預測(2026-2034 年)

Transplant Diagnostics Market Report Size, Share, Trends and Forecast by Component, Technology, Organ Type, Application, End User, and Region, 2026-2034

出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年全球移植診斷市場規模為10.063億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到18.595億美元,2026年至2034年的複合年成長率(CAGR)為6.85%。目前,北美市場主導地位,預計2025年將佔據34.6%的市場。推動該市場成長的因素包括器官移植數量的增加,以及對準確、快速、非侵入性診斷系統的需求不斷成長,這些系統用於確認移植相容性並追蹤移植後情況。此外,分子診斷、次世代定序和生物資訊學的進步正在提高供受者相容性、排斥風險和感染疾病追蹤的檢測準確性。同時,醫療保健支出的成長和政府支持計畫也進一步推動了移植診斷市場佔有率的提升。

非侵入性診斷方法的進步、個人化醫療的日益普及以及醫療基礎設施投資的增加,共同推動了這個市場的發展。此外,許多國家醫療保健支出的成長也促進了市場擴張。根據產業報告顯示,2021年全球醫療保健支出達到創紀錄的9.8兆美元,佔全球GDP的10.3%。同時,人們對器官捐贈的認知不斷提高,加上世界衛生組織的支持性政策,使得更多人能夠獲得器官移植手術。此外,人工智慧(AI)在診斷流程中的應用提高了排斥風險預測的準確性。診斷公司與醫療服務提供者之間的策略合作進一步加速了創新,確保為全球移植專案提供準確、經濟高效且擴充性的診斷解決方案。

在美國,健全的法規結構、高昂的醫療費用支出以及尖端診斷技術的廣泛應用正在推動市場發展。此外,擁有先進檢測能力的專業移植中心的存在,使得快速可靠的相容性檢測成為可能。移植診斷市場的一個新興趨勢是,優惠的保險覆蓋範圍和報銷政策的擴大,這刺激了高價值分子和基因組檢測的應用。此外,促進器官捐贈的支持性措施和模式也支持市場發展。例如,2024年11月,美國醫療保險和醫療補助服務中心(CMS)最終確定了一項為期六年的強制性“增加器官移植機會(IOTA)模式”,旨在改善腎移植的機會、提高醫療質量、最佳化醫療協調、減少醫療資源分配不均以及降低醫療保險成本。該模式計劃於 2025 年 7 月 1 日開始實施,涉及 103 家腎臟移植醫院,將透過基於績效的經濟獎勵和懲罰措施,促進移植數量的增加、器官接受速度和效率的提高,以及移植存活率的提高。

移植診斷市場的發展趨勢:

老年人口增加

全球老年人口的不斷成長為該市場帶來了巨大的成長機會。老年患者罹患與老齡化相關的退化性疾病和慢性疾病(例如心血管疾病、腎衰竭和肝病)的風險更高,這些疾病通常需要器官移植。產業報告顯示,約93%的65歲以上成年人患有至少一種慢性疾病,約79%患有兩種或兩種以上慢性疾病。此外,外科技術的進步和術後護理的改善使得老年患者接受器官移植的可能性越來越大,從而擴大了潛在候選者的範圍。老年人的免疫系統面臨獨特的挑戰,需要精準而精密的診斷技術來確定相容性並有效控制排斥反應的風險。此外,移植前後的分子檢測和基於生物標記的監測對於實現該患者群體的最佳治療至關重要。隨著全球預期壽命的延長,醫療保健系統面臨著老年族群器官移植需求的不斷成長,這直接推動了對精準、高效、快速的移植診斷解決方案的需求,這些解決方案必須能夠適應老年患者管理的複雜性。

慢性病增多

由於加工食品消費量的增加以及吸菸和飲酒人數的成長,急慢性疾病的盛行率不斷上升,導致器官衰竭病例顯著增加。這反過來又對移植診斷市場的前景產生了積極影響。報告顯示,到2030年,慢性疾病負擔預計將達到約47兆美元。此外,慢性腎臟病、肝硬化和心臟衰竭等疾病往往會發展為末期器官衰竭,此時移植成為最現實的治療選擇。這些慢性疾病盛行率的上升與營養不良、缺乏運動、超重或肥胖等生活方式選擇以及糖尿病和高血壓的增加密切相關。在任何移植過程中,全面的移植前和移植後診斷評估,包括HLA型檢測、交叉配對試驗和免疫監測,對於實現患者最佳治療效果至關重要。慢性疾病負擔的加重不僅增加了移植候選人的數量,而且還推動了先進分子診斷和血清學檢測技術的應用,以提高相容性檢測的準確性,降低器官排斥的風險,並最大限度地提高各種器官的長期移植存活率。

嚴重交通事故增加

嚴重交通事故發生率的上升間接推動了移植診斷市場的成長,因為這增加了已故捐贈者的器官供應。根據業界報告顯示,全球每年約有119萬人死於交通事故。創傷性腦損傷和致命事故往往會導致可移植器官的捐獻,而這些器官對於滿足日益成長的移植需求至關重要。從這些案例中取得捐贈器官,使得在有限的時限內快速可靠地確定供體與受體的匹配度變得特別迫切。此外,即時PCR、次世代定序和先進的交叉配對試驗等技術在確保準確匹配和降低排除風險方面發揮關鍵作用。另外,事故發生率高的地區通常有完善的器官捐贈系統,進一步加速了移植診斷技術的應用。由於器官短缺仍然是全球面臨的挑戰,不幸的是,致命事故的增加無意中加劇了移植醫學領域對快速準確診斷工具的需求。

目錄

第1章:序言

第2章:調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章:引言

第5章:全球移植診斷市場報告

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔:依組件分類

  • 設備/器材
  • 試劑和耗材
  • 軟體和服務

第7章 市場區隔:依技術分類

  • 非分子檢測
    • 主要部分
      • 血清學檢測
      • 混合淋巴球培養
  • 分子檢測
    • 主要部分
      • 基於PC
      • 定序鹼基

第8章 市場細分:依器官類型分類

  • 胰臟
  • 其他

第9章 市場區隔:依應用領域分類

  • 移植前診斷
  • 移植後診斷

第10章 市場區隔:依最終用戶分類

  • 醫院及移植中心
  • 研究機構和學術機構
  • 商業服務供應商

第11章 市場區隔:按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章:價值鏈分析

第14章:波特五力分析

第15章:價格分析

第16章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Becton Dickinson and Company
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • Hologic Inc
    • Illumina Inc.
    • Immucor Inc.(IVD Holdings Inc.)
    • Merck KGaA
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A4436

The global transplant diagnostics market size was valued at USD 1,006.3 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 1,859.5 Million by 2034, exhibiting a CAGR of 6.85% during 2026-2034. North America currently dominates the market, holding a significant market share of around 34.6% in 2025 . The market is fueled by the increasing incidences of organ transplants and increasing demand for precise, fast, and non-invasive diagnostic systems to verify transplant compatibility and track post-transplant status. Furthermore, advances in molecular diagnostics, next-generation sequencing, and bioinformatics are facilitating enhanced detection of donor-recipient compatibility, risk of rejection, and infection tracking. Besides that, rising healthcare spending and supportive government programs are further augmenting the transplant diagnostics market share.

The market is propelled by advancements in non-invasive testing methods, increasing adoption of personalized medicine, and growing investments in healthcare infrastructure. Furthermore, the rising government spending on healthcare across numerous nations is driving market expansion. According to an industry report, global healthcare spending hit an all-time high of USD 9.8 Trillion in 2021, representing 10.3% of the global GDP. Besides this, rising awareness about organ donation, coupled with supportive policies from international health organizations, is fostering broader access to transplantation procedures. Additionally, the integration of artificial intelligence in diagnostic workflows is enhancing predictive accuracy for rejection risks. Also, strategic collaborations between diagnostic companies and healthcare providers are further accelerating innovation, ensuring the availability of precise, cost-efficient, and scalable testing solutions for global transplant programs.

In the United States, the market is driven by a strong regulatory framework, high healthcare spending, and extensive adoption of cutting-edge diagnostic technologies. Moreover, the presence of specialized transplant centers with advanced laboratory capabilities facilitates rapid and reliable compatibility testing. One of the emerging transplant diagnostics market trends is the expansion of favorable insurance coverage and reimbursement policies, which encourage the use of high-value molecular and genomic assays. Apart from this, supportive initiatives and models promoting organ donation are supporting market development. For instance, in November 2024, the Centers for Medicare & Medicaid Services (CMS) finalized the six-year mandatory Increasing Organ Transplant Access (IOTA) Model, aimed at improving access to kidney transplants, enhancing quality of care, optimizing care coordination, reducing disparities, and lowering Medicare costs. Scheduled to begin on July 1, 2025, the model will involve 103 kidney transplant hospitals and will employ performance-based financial incentives and penalties to encourage increased transplant volumes, faster and more efficient organ offer acceptance, and improved graft survival rates.

TRANSPLANT DIAGNOSTICS MARKET TRENDS:

Expanding Geriatric Population

The global rise in the geriatric population is creating substantial growth opportunities for the market. Older patients are at higher risk of degenerative age-related conditions and chronic diseases like cardiovascular disease, renal failure, and liver disease, which often require transplantation of organs. According to an industry report, approximately 93% of adults aged 65 years and over suffer from at least one chronic illness. Approximately 79% suffer from two or more. Moreover, improved surgical methods and care after surgery have made transplantation increasingly possible for older patients, increasing the pool of potential candidates. The older immune system poses special challenges, with accurate and sophisticated diagnostics needed to determine compatibility and effectively control rejection risks. Additionally, pre- and post-transplant molecular testing and biomarker-directed monitoring are especially important in this population to achieve optimal therapy. With the increasing longevity of people worldwide, healthcare systems have been experiencing increased demand for organ transplantation among the elderly population, directly driving up the demand for accurate, effective, and speedy transplant diagnostic solutions compatible with the intricacies of geriatric patient management.

Rising Chronic Diseases

The growing prevalence of acute and chronic diseases on account of the increasing consumption of processed food products and the escalating number of individuals who smoke tobacco products and consume alcohol is causing a significant rise in the number of organ failure cases. This, in turn, is positively impacting the transplant diagnostics market outlook. According to reports, the burden of chronic diseases is projected to reach approximately USD 47 Trillion by 2030. Moreover, diseases like chronic kidney disease, cirrhosis, and heart failure tend to advance to end-stage organ failure, where transplantation is the most viable treatment option. This increased prevalence of chronic diseases correlates with lifestyle choices, such as poor nutrition, lack of activity, and overweight/obesity, and the increase in diabetes and hypertension. Every transplant process entails extensive pre- and post-transplant diagnostic evaluation, such as HLA typing, crossmatching, and immune monitoring, to provide the best possible outcomes for patients. The escalating chronic disease burden is not only increasing the number of transplant candidates but also leading to the implementation of sophisticated molecular and serological testing technologies in order to enhance compatibility testing, minimize chances of organ rejection, and maximize long-term graft survival rates for different types of organs.

Escalating Number of Severe Road Accidents

The rising incidence of severe road accidents is indirectly contributing to the transplant diagnostics market growth by increasing the availability of organs from deceased donors. As per industry reports, around 1.19 Million people lose their lives each year worldwide as a result of road accidents. Traumatic brain injuries and fatal accidents often result in viable organ donations, which are vital to meeting the growing demand for transplants. The availability of donor organs from such cases triggers the immediate need for fast and reliable diagnostic testing to determine donor-recipient compatibility within tight timeframes. Furthermore, technologies like real-time PCR, next-generation sequencing, and advanced crossmatching assays play a crucial role in ensuring accurate matching and reducing rejection risks. Besides this, regions with high accident rates often have robust organ procurement systems in place, further accelerating the use of transplant diagnostics. As organ shortages remain a global challenge, the unfortunate rise in fatal accidents is inadvertently sustaining the demand for rapid, high-precision diagnostic tools in transplant medicine.

TRANSPLANT DIAGNOSTICS INDUSTRY SEGMENTATION:

Analysis by Component:

  • Instrument and Equipment
  • Reagent and Consumables
  • Software and Services

Reagent and consumables lead the market in 2025. The segment constitutes the foundation of laboratory testing protocols. They are test kits, assay reagents, buffers, and disposable lab supplies utilized for HLA typing, crossmatching, and detection of antibodies. Their continual demand arises from the fact that every diagnostic test demands fresh and accurate materials for guaranteed accurate and reliable results, which have a direct bearing on transplant compatibility tests. As organ transplant success is highly dependent on reducing the risks of rejection, the quality and availability of such consumables are critical. Moreover, the increasing rate of transplant procedures being performed globally, along with the development of molecular and serological testing technology, fuels consistent market growth for these products. Suppliers are aided by a repeat business model, as the labs need to constantly restock, and the reagents and consumables are not only critical to clinical pathways but also a big revenue division in the market.

Analysis by Technology:

  • Non-Molecular Assay
    • Serological Assay
    • Mixed Lymphocyte Culture
  • Molecular Assay
    • PC-based
    • Sequencing-based

Molecular assay leads the market with around 42.6% of market share in 2025. They are precise, fast, and can identify genetic differences at a detailed level. Such tests, involving PCR-based techniques and next-generation sequencing (NGS), are extensively applied to HLA typing, donor-specific antibody detection, and monitoring post-transplant immune status. By confirming gene compatibility among donors and recipients with precise accuracy, molecular tests decrease organ rejection risk and enhance long-term graft survival. Their use is increasing as healthcare systems move toward more individualized and streamlined transplant evaluation processes. The technology's capability to rapidly handle complex genetic information aids in making timely decisions, important in transplant situations in which time sensitivity can determine patient outcomes. With ongoing developments, molecular assays are transforming the future of transplant diagnostics, rendering them invaluable in pre-transplant screening and post-transplant monitoring.

Analysis by Organ Type :

  • Kidney
  • Liver
  • Heart
  • Lung
  • Pancreas
  • Others

Kidney leads the market in 2025 due to the large prevalence of end-stage renal failure and chronic kidney disease globally. Timely and accurate diagnostics in this segment are critical to avoid incompatibility between the donor and recipient, minimize rejection risk, and maximize graft survival rates. These include tests like HLA typing, crossmatching, and detection of donor-specific antibodies, which are applied on a routine basis prior to and after kidney transplants, making diagnosis a part of the treatment process. Transplant diagnostics in kidney transplants are also bolstered by increased numbers of live and cadaveric donor transplants, as well as technology developed in molecular diagnostics that can furnish quicker and more accurate results. Since kidney transplants continue to be the most prevalent solid organ transplant, they are still a driving force for revenue and innovation in the market.

Analysis by Application:

  • Pre-Transplant Diagnostics
  • Post-Transplant Diagnostics

Pre-transplant diagnostics are critical to assess donor-recipient compatibility and reduce the threat of graft rejection. Such tests comprise HLA typing, crossmatch, and donor-specific antibody screening, all of which identify the optimal match prior to surgery. Precise pre-transplant evaluation increases the success rate of transplants, minimizes complications, and facilitates improved long-term outcomes. Infectious disease workup is also done in addition to compatibility testing to avoid transmission of infection during transplantation. The increase in organ transplant demand and organ unavailability renders accurate and efficient pre-transplant diagnostics essential for making timely decisions. Advances in molecular tests and automation further increase test accuracy and efficiency, reinforcing their role as a cornerstone step in the process of transplantation.

Post-transplant diagnostics target the surveillance of the recipient's immune reaction to identify early indicators of rejection or infection. The tests involved are donor-specific antibody measurement, biomarker determination, and molecular testing to determine the function of the graft and immune activity. Continuous post-transplant monitoring enables clinicians to modulate immunosuppressive therapy early in the course of disease, averting irreversible transplanted organ damage. The increased uptake of non-invasive and quick testing technologies enhanced the comfort of patients and facilitated more regular monitoring, resulting in improved long-term graft survival rates. Since organ rejection may take months or years to be observed following surgery, demand for trusted post-transplant diagnosis continues to be robust. Ongoing innovation in this space is broadening the capacity for earlier detection of complications and is an essential part of integrated transplant medicine.

Analysis by End User :

  • Hospitals and Transplant Centers
  • Research Laboratories and Academic Institutes
  • Commercial Service Providers

Hospitals and transplant centers are one of the key end users as they have direct responsibility for patient evaluation, surgery, and post-operative care. Transplant centers depend on sophisticated diagnostic instrumentation to do HLA typing, crossmatching, and immune monitoring, maximizing donor-recipient compatibility and minimizing rejection. With the increasing number of transplant procedures globally, hospitals are increasingly implementing fast and precise molecular and serological diagnostic testing methodologies to enhance patient outcomes. Most transplant centers also have specialized laboratories within their premises, allowing for quicker turnaround times for urgent diagnostic results. Their place is not just pivotal in clinical decision-making but also in managing multidisciplinary teams, thereby a prime driver for demand in the transplant diagnostics market.

Research institutes and academic institutions are involved in the market by adding innovation, method development, and validation of novel testing methods. They are engaged in developing molecular assays, discovery of biomarkers, and genomic technology to make transplants more successful and minimize complications. They are also significantly involved in clinical trials to evaluate new diagnostic tools before using them in hospitals and commercial applications. Cooperation among scientific centers and industry players serves to convert the results of research into applicable diagnostic solutions. Besides, these companies equip medical specialists and scientists with training, thereby providing the transplant community with a qualified workforce. Their efforts lead to ongoing improvement in diagnostic precision, sensitivity, and economic efficiency, which further consolidates their place in the overall transplant diagnostics system.

Commercial service providers provide specialized transplant diagnostic tests on behalf of hospitals, transplant programs, and research institutions. These firms tend to have centralized labs with high-end technologies, allowing them to provide high-throughput and accurate testing services. With outsourcing to commercial vendors, healthcare facilities can obtain specialized knowledge and complex molecular tests without huge investments in infrastructure. This is highly beneficial for small centers with limited internal capabilities. Commercial vendors also help with quality assurance, compliance with regulations, and implementation of state-of-the-art technologies, including next-generation sequencing. Their efficiency, scalability, and capacity to work with numerous clients across regions make them a fundamental piece in bridging access to timely and reliable transplant diagnostics globally.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 34.6% driven by the region's robust healthcare infrastructure, intensive use of sophisticated diagnostic technologies, and significant presence of top industry players. Moreover, the high rate of organ transplant surgeries, fueled by increasing numbers of chronic illnesses like kidney and liver failure, provides a boost to the market. Transplant centers and hospitals in the US and Canada employ cutting-edge molecular assays, next-generation sequencing, and serological testing to provide precise donor-recipient matching as well as efficient post-transplant monitoring. Supportive reimbursement policies, government programs to encourage organ donation, and research collaborations continue to enhance the market. Furthermore, North America's emphasis on innovation and high clinical trial activity rate continues to fuel advances in transplant diagnostic techniques.

KEY REGIONAL TAKEAWAYS:

UNITED STATES TRANSPLANT DIAGNOSTICS MARKET ANALYSIS

In 2025, the United States holds a substantial share of around 88.70% of the transplant diagnostics share in North America. The market driven by a sharp rise in chronic diseases, particularly kidney failure, diabetes, heart conditions, and liver diseases, which is increasing the demand for organ transplants in top-tier medical centers nationwide. According to an industry report published in 2024, in the United States, an estimated 129 million individuals are affected by at least one major chronic illness, such as heart disease. Moreover, 42% suffer from two or more, while 12% suffer from as many as 5. Additionally, advancements in molecular diagnostics, particularly in the areas of human leukocyte antigen (HLA) typing and next-generation sequencing, have significantly improved donor-recipient matching and transplant outcomes, increasing the adoption of sophisticated diagnostic tools. Furthermore, growing awareness among healthcare professionals and patients about the importance of early and accurate diagnostic testing in transplantation is fueling market growth. The expansion of organ transplant programs and supportive government initiatives to improve transplant infrastructure have further heightened the need for reliable diagnostic systems. The presence of technologically advanced healthcare facilities and a favorable reimbursement environment are also contributing to increased diagnostic testing. Other than this, increased investments in research and development (R&D) by key market players are resulting in more accurate, faster, and cost-effective diagnostic tools.

ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET ANALYSIS

In Asia-Pacific, the market is expanding due to the rapid expansion of healthcare infrastructure and transplant programs across the region, which is increasing access to crucial diagnostic testing. For instance, in March 2023, India's healthcare infrastructure comprises a total of 1,69,615 Sub-Centres (SCs), 31,882 Primary Health Centres (PHCs), 6,359 Community Health Centres (CHCs), 1,340 Sub-Divisional/District Hospitals (SDHs), 714 District Hospitals (DHs), and 362 Medical Colleges (MCs), spanning both urban and rural regions. Moreover, the increasing adoption of digital health technologies and laboratory automation, which enhance the efficiency and accuracy of diagnostic workflows, is also supporting industry expansion. The integration of artificial intelligence (AI) and machine learning (ML) in diagnostic platforms is also contributing to improved interpretation of complex genetic data, supporting more informed clinical decisions. Besides this, government support for transplant initiatives and favorable reimbursement policies in key nations are also encouraging the adoption of sophisticated testing systems.

EUROPE TRANSPLANT DIAGNOSTICS MARKET ANALYSIS

The growth of the market in Europe is largely propelled by technological innovations and evolving healthcare policies. An increasing geriatric population and rising incidence of chronic conditions such as kidney disease, liver failure, and cardiometabolic disorders have heightened the demand for organ transplantation and associated diagnostics. According to reports, the number of individuals aged 65 years and older in the European Union accounted for 21.6% of the population of the region in January 2024. In parallel, breakthroughs in immunogenetics, advanced tissue-typing platforms, and non-invasive biomarker assays are enabling more precise donor matching, early rejection detection, and optimal long-term graft health. Increased awareness among clinicians and patients about the critical role of timely and accurate diagnostics in transplantation processes is also fueling uptake. Moreover, cross-border healthcare initiatives and funding under pan-European health programs are strengthening transplant networks, harmonizing diagnostic standards, and improving access across countries. A supportive reimbursement environment and alignment with personalized medicine strategies are also encouraging hospitals and laboratories to invest in sophisticated testing systems. Additionally, collaborative research efforts among academic institutions, biotech firms, and diagnostic companies are accelerating the commercialization of next-generation assays tailored to European regulatory frameworks. The growing emphasis on quality metrics, audit compliance, and real-world patient outcomes is further driving the adoption of standardized, high-sensitivity diagnostic solutions.

LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET ANALYSIS

In Latin America, the market is significantly influenced by a growing focus on improving transplant success rates through personalized medicine and precision diagnostics. As healthcare systems strive to reduce post-transplant complications and improve long-term patient outcomes, there is an increasing demand for advanced immunological monitoring and molecular diagnostic tools. The gradual adoption of digital health and data integration technologies is also enhancing clinical decision-making and streamlining diagnostic processes. For instance, the digital health market in Brazil reached USD 10.66 Billion in 2024 and is projected to reach USD 40.85 Billion by 2033, growing at a CAGR of 16.10% during 2025-2033. Besides this, gradual enhancements in healthcare financing, insurance coverage, and reimbursement policies are making sophisticated transplantation diagnostics more accessible, supporting market growth.

MIDDLE EAST AND AFRICA TRANSPLANT DIAGNOSTICS MARKET ANALYSIS

The market in the Middle East and Africa is experiencing robust growth due to the expansion of specialty healthcare facilities and the establishment of regional transplant centers catering to growing patient demand. Increasing investment in modern clinical laboratories is enabling access to advanced diagnostic methods such as immunogenetic profiling and multiplex biomarker assays. Governments in the region are also progressively prioritizing organ transplantation as part of national healthcare strategies, leading to improved funding and support for transplant-related services, including diagnostics. Additionally, the rising burden of non-communicable diseases, such as diabetes and hypertension, is leading to increased cases of organ failure and transplant need. An industry report indicates that the Middle East and North Africa region currently has 85 Million people living with diabetes, which is projected to rise to 163 million by 2050.

COMPETITIVE LANDSCAPE:

The market is characterized by intense innovations, led by the growing need for effective, timely, and non-invasive diagnostic products that can enhance patient outcomes in organ transplantation. Market players compete based on advancements in molecular diagnostics, next-generation sequencing (NGS), and polymerase chain reaction (PCR) technologies to deliver improvements in donor-recipient matching and post-transplant monitoring. Moreover, strategic partnerships with healthcare centers and research institutions are not uncommon, facilitating access to cutting-edge technology and increased global presence. In addition, regulatory compliance, quality control, and the capacity to deliver cost-efficient test solutions are foremost determinants of competitiveness. According to the transplant diagnostics market forecast, increasing transplant volumes, increasing knowledge of graft rejection detection in the early stage, and the incorporation of AI-powered data analytics are expected to sharpen competition between market players. Besides this, the emphasis on creating multiplex assays and custom testing solutions is opening new paths for differentiation, while regional growth strategies are being pursued to leverage emerging healthcare markets.

The report provides a comprehensive analysis of the competitive landscape in the transplant diagnostics market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Becton Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG
  • Hologic Inc.
  • Illumina Inc.
  • Immucor Inc. (IVD Holdings Inc.)
  • Merck KGaA
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the transplant diagnostics market?

2. What is the future outlook of the transplant diagnostics market?

3. What are the key factors driving the transplant diagnostics market?

4. Which region accounts for the largest transplant diagnostics market?

5. Which are the leading companies in the global transplant diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Transplant Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Instrument and Equipment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Reagent and Consumables
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software and Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Non-Molecular Assay
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Serological Assay
      • 7.1.2.2 Mixed Lymphocyte Culture
    • 7.1.3 Market Forecast
  • 7.2 Molecular Assay
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 PC-based
      • 7.2.2.2 Sequencing-based
    • 7.2.3 Market Forecast

8 Market Breakup by Organ Type

  • 8.1 Kidney
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Liver
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Heart
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Lung
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Pancreas
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Pre-Transplant Diagnostics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Post-Transplant Diagnostics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals and Transplant Centers
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Research Laboratories and Academic Institutes
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Commercial Service Providers
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Abbott Laboratories
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Becton Dickinson and Company
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 bioMerieux SA
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Bio-Rad Laboratories Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 F. Hoffmann-La Roche AG
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 SWOT Analysis
    • 16.3.6 Hologic Inc
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Illumina Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Immucor Inc. (IVD Holdings Inc.)
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 SWOT Analysis
    • 16.3.9 Merck KGaA
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Qiagen N.V.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Thermo Fisher Scientific Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Transplant Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Transplant Diagnostics Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Transplant Diagnostics Market: Breakup by Component (in %), 2025
  • Figure 5: Global: Transplant Diagnostics Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Transplant Diagnostics Market: Breakup by Organ Type (in %), 2025
  • Figure 7: Global: Transplant Diagnostics Market: Breakup by Application (in %), 2025
  • Figure 8: Global: Transplant Diagnostics Market: Breakup by End User (in %), 2025
  • Figure 9: Global: Transplant Diagnostics Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Transplant Diagnostics (Instrument and Equipment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Transplant Diagnostics (Instrument and Equipment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Transplant Diagnostics (Reagent and Consumables) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Transplant Diagnostics (Reagent and Consumables) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Transplant Diagnostics (Software and Services) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Transplant Diagnostics (Software and Services) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Transplant Diagnostics (Non-Molecular Assay) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Transplant Diagnostics (Non-Molecular Assay) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Transplant Diagnostics (Molecular Assay) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Transplant Diagnostics (Molecular Assay) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Transplant Diagnostics (Kidney) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Transplant Diagnostics (Kidney) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Transplant Diagnostics (Liver) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Transplant Diagnostics (Liver) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Transplant Diagnostics (Heart) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Transplant Diagnostics (Heart) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Transplant Diagnostics (Lung) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Transplant Diagnostics (Lung) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Transplant Diagnostics (Pancreas) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Transplant Diagnostics (Pancreas) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Transplant Diagnostics (Other Organ Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Transplant Diagnostics (Other Organ Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Transplant Diagnostics (Pre-Transplant Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Transplant Diagnostics (Pre-Transplant Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Transplant Diagnostics (Post-Transplant Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Transplant Diagnostics (Post-Transplant Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Transplant Diagnostics (Hospitals and Transplant Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Transplant Diagnostics (Hospitals and Transplant Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Transplant Diagnostics (Research Laboratories and Academic Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Transplant Diagnostics (Research Laboratories and Academic Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Transplant Diagnostics (Commercial Service Providers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Transplant Diagnostics (Commercial Service Providers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: North America: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: North America: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: United States: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: United States: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Canada: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Canada: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Asia-Pacific: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Asia-Pacific: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: China: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: China: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Japan: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Japan: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: India: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: India: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: South Korea: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: South Korea: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Australia: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Australia: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Indonesia: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Indonesia: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Others: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Others: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Europe: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Europe: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Germany: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Germany: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: France: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: France: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: United Kingdom: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: United Kingdom: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Italy: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Italy: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Spain: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Spain: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Russia: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Russia: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Latin America: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Latin America: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Brazil: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Brazil: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Mexico: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Mexico: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Others: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Others: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Middle East and Africa: Transplant Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Middle East and Africa: Transplant Diagnostics Market: Breakup by Country (in %), 2025
  • Figure 90: Middle East and Africa: Transplant Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Global: Transplant Diagnostics Industry: SWOT Analysis
  • Figure 92: Global: Transplant Diagnostics Industry: Value Chain Analysis
  • Figure 93: Global: Transplant Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Transplant Diagnostics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Transplant Diagnostics Market Forecast: Breakup by Component (in Million USD), 2026-2034
  • Table 3: Global: Transplant Diagnostics Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Transplant Diagnostics Market Forecast: Breakup by Organ Type (in Million USD), 2026-2034
  • Table 5: Global: Transplant Diagnostics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 6: Global: Transplant Diagnostics Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 7: Global: Transplant Diagnostics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Transplant Diagnostics Market: Competitive Structure
  • Table 9: Global: Transplant Diagnostics Market: Key Players